Theriva Biologics reports Q3 results, extends cash runway to Q1 2027.

Theriva Biologics presented data on its VCN-01 treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) in the VIRAGE Phase 2b trial at ESMO 2025. The company also presented preclinical data on its VCN-12 oncolytic virus at ESGCT 2025. Theriva Biologics reported $7.5 million in cash and equivalents as of September 30, 2025, which increased to $15.5 million after recent capital raises, extending liquidity until Q1 2027.